SIENDO Trial with Ignace Vergote

IJGC Podcast - A podcast by BMJ Group - Mondays

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Em. Ignace Vergote to discuss the SIENDO Trial. Prof. Vergote was Chairman of the Department of Gynaecology and Obstetrics at the Catholic University Leuven from 2003-2020. He published more than 1050 papers on gynecologic cancer in peer-reviewed journals and his work was cited more than 88,000 times. He served as President of IGCS, ESGO, EORTC-GCG and ENGOT.   Highlights: Selinexor inhibits Exportin-1, resulting in reactivation of Tumor Suppressor Proteins (especially p53) in the nucleus. This leads to selective killing of cancer cells. The ENGOT-EN5/GOG-3055/SIENDO was a randomized phase III double-blind trial comparing maintenance selinexor with placebo, after response on chemotherapy in patients with advanced or first recurrence of endometrial cancer. Median PFS in the ITT population was 5.7 versus 3.8 months (not significant). Long-term PFS in TP53wt patients was 27.4 months and 5.3 months (HR 0.41) and in TP53wt/pMMR patients not reached and 4.9 months (HR: 0.32) for selinexor and placebo, respectively. Selinexor is very promising in patients with advanced/recurrent TP53wt endometrial cancer and is further investigated in this population in the ongoing ENGOT-EN20/GOG-3083/XPORT-042 study.